和铂医药-B(02142)今日盘中股价强劲上涨,引发市场广泛关注。海通证券分析师周瑜表示,该股上涨主要源于公司新药项目取得重大利好进展。
和铂医药公告显示,其针对慢性阻塞性肺病的全人源单克隆抗体HBM9378/SKB378已获中国药监局批准开展临床试验。该抗体作用于重要病理靶点胸腺基质淋巴细胞生成素,有望成为治疗COPD的重磅新药。COPD是一种严重且高发的慢性呼吸系统疾病,在全球范围内的患病率和治疗需求均较大。
COPD领域临床急需新的创新疗法,如果HBM9378后续研发顺利,不仅有望接入广阔市场,为公司带来新的收入增长点,也将有助扩充产品管线,巩固和铂医药在免疫及呼吸领域的领先地位。市场人士认为,这是和铂医药长期投资价值的重要体现,因此推动股价出现明显上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.